Pharmaceuticals & Therapeutics

A new report reveals payers are rewriting drug benefit rules, sacrificing rebates for more control as they grapple with the high cost of new therapies.

With investments exceeding $1B, PCI Pharma Services is expanding its US sterile manufacturing, tackling supply chain risks and boosting domestic production.

WACKER is set to reveal a cost-saving XRF testing method and a breakthrough gamma-sterilizable medical adhesive, poised to impact two key sectors.

Milwaukee's Zurn Elkay named a top US Climate Leader again, proving that deep cuts in emissions can fuel business success and solve real-world water issues.

In a key human trial, Sona Nanotech's heat-based therapy saw a 60% complete response in tumors for melanoma patients who had exhausted other options.

With 65% of its medical tourism revenue from Indonesia, Malaysia is doubling down on its most vital market through strategic outreach and world-class care.

A new competition connects emerging shelf-stable brands with 200+ retail buyers, offering a direct path to national shelf space in a crowded market.

A landmark $41M donation from the Weston family to Sunnybrook aims to overhaul Canada's clinical trial landscape, promising faster patient access to therapies.

Citius Pharmaceuticals raises crucial capital for its new cancer drug, but the deal's structure prompts a classic biotech debate: growth vs. shareholder value.

Millions are using GLP-1 drugs for weight loss, but an unexpected side effect is emerging: a prominent 'buffalo hump' that surgery is now targeting.

A new partnership brings a psychology-based diabetes reversal program to millions, offering a corporate-funded alternative to popular GLP-1 medications.

In a landmark decision, the DEA has rescheduled medical cannabis, unlocking scientific research, slashing industry taxes, and reshaping patient access.

As GLP-1 costs cripple employer health plans, Noom Health's new program bypasses industry middlemen, projecting massive savings and better patient outcomes.

U.S. Anesthesia Partners will settle a major antitrust lawsuit, signaling a victory for federal regulators and new rules for healthcare consolidation.

A new study reveals that poor muscle quality, measured by advanced MRI, is a powerful predictor of death in CKD patients, shifting focus to systemic health.

Canadian giant Apotex acquires Cumberland's U.S. branded drugs for $100M, a move that expands its hospital presence and pivots Cumberland to a biotech.

Backed by military funding, a novel protein therapy that actively grows bone has finished a key clinical trial, promising to revolutionize dental surgery.

A Montreal agency’s innovative campaign for DEX4 is changing the conversation around hypoglycemia by turning a moment of anxiety into an act of empowerment.

A new T-cell therapy, RPTR-1-201, enters clinical trials, offering hope for hard-to-treat solid tumors by targeting a shared, multi-cancer marker.

Winning top awards, China's Fosun Health unveils a bold strategy to become the premier gateway for Southeast Asian patients seeking advanced medical care.